Cartherics Pty Ltd
- Company typePrivate
- Founded2014
- HeadquartersMelbourne, Australia
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
Cartherics Pty Ltd firmographics
Firmographics- Name
- Cartherics Pty Ltd
- Legal name
- Cartherics Pty Ltd
- Website
- https://cartherics.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Cartherics Pty Ltd industry classification
Industry- Product category
- Cancer Immunotherapy / Cell Therapy
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- NK Cell Therapies (HLAAABAD)
- akta.pro secondary industry
- Cell Therapy Developers (Allogeneic/Off-the-shelf) (HLAAABAB)
Keywords
Where Cartherics Pty Ltd is headquartered
LocationHeadquarters
- HQ city
- Melbourne
- HQ country
- Australia
- HQ region
- Oceania
Offices1 record
Markets served
Cartherics Pty Ltd business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales
Revenue model
- Cell Therapy Commercialization: Pre-commercial stage biotechnology company developing CAR-NK cell therapies. Revenue will be generated through commercialization of approved cell therapy products for cancer and endometriosis treatment. The company is working toward bringing CTH-401 and pipeline products to market.
- Licensing and Manufacturing Partnerships: Revenue may be generated through licensing agreements and manufacturing partnerships as the company advances its pipeline toward commercialization, leveraging the Catalent partnership for late-stage and commercial manufacturing support.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels2 records
Cartherics Pty Ltd product offering
Product offeringCore offering
Cartherics develops off-the-shelf allogeneic CAR-NK (Chimeric Antigen Receptor Natural Killer) cell therapies derived from induced pluripotent stem cells (iPSCs). Its lead candidate, CTH-401, targets the TAG-72 tumor antigen for the treatment of ovarian cancer, with the broader pipeline aimed at solid tumors and endometriosis. Manufacturing leverages a cGMP-compliant iPSC line licensed from Catalent.
Product overview
Cartherics is developing off-the-shelf CAR-NK cell therapies using an iPSC-derived platform. The company's lead product is CTH-401, a CAR-NK therapy targeting TAG-72 for ovarian cancer. The pipeline also includes programs targeting endometriosis. Manufacturing is supported through a partnership with Catalent using their cGMP-compliant iPSC line, with FDA regulatory clearance obtained for the lead candidate.
Differentiator
Problem solved
Functional benefit
Quantifiable outcome
- Initiating first clinical trial for CTH-401 in ovarian cancer in 2025
Companies that use Cartherics Pty Ltd
Customer profileSegments3 records
Ideal customer profiles3 records
Cartherics Pty Ltd technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Cartherics Pty Ltd partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Catalent, Inc.coreCartherics signed an amended commercial license agreement with Catalent to use their cGMP-compliant induced pluripotent stem cell (iPSC) line for manufacturing and commercializing CAR-NK products, including lead candidate CTH-401. The partnership enables Cartherics to leverage Catalent's established GMP-grade iPSC platform and validated workflows for cost-effective production. Both companies expressed confidence that the collaboration will advance Cartherics' programs toward commercialization.
Scale indicators4 records
Recent moves6 records
Expansion highlights5 records
Cartherics Pty Ltd competitors and assessment
Company assessmentEmerging players
- Gamida Cell: Cell therapy company with an approved allogeneic stem cell product (Omisirge) and NK cell programs. Comparable as a smaller allogeneic cell therapy peer with regulatory and commercial experience in similar modalities.
- Caribou Biosciences: Clinical-stage allogeneic CAR-T and NK cell therapy developer using CRISPR-based gene editing. Comparable as an allogeneic cell therapy developer with overlapping modality but differentiated gene-editing approach.
Direct peers
- Century Therapeutics: Clinical-stage company developing allogeneic iPSC-derived cell therapies including NK and T-cell candidates for oncology. Shares Cartherics's iPSC-based allogeneic manufacturing strategy and oncology indication focus.
- Fate Therapeutics: Develops off-the-shelf iPSC-derived NK and T-cell therapies for cancer and autoimmune disease. Fate's iPSC-derived platform closely mirrors Cartherics's core manufacturing approach and is the most relevant platform peer.
- MiNK Therapeutics: Clinical-stage company developing allogeneic NK cell therapies (including iNKT and CAR-NK candidates) for solid tumors. Direct modality and indication overlap with Cartherics's CAR-NK ovarian cancer program.
- Nkarta Therapeutics: Clinical-stage biotech developing allogeneic CAR-NK cell therapies for cancer, with a similar off-the-shelf platform and oncology focus. Nkarta is the most directly comparable CAR-NK pure-play peer.
- Allogene Therapeutics: Clinical-stage allogeneic CAR-T developer with multiple oncology programs in clinical development. Highly comparable as a competing allogeneic cell therapy developer with broader pipeline scale and similar regulatory pathway.
- Shoreline Biosciences: Develops allogeneic NK and macrophage cell therapies engineered via iPSC and other platforms for cancer. Comparable as a directly competing allogeneic NK cell therapy developer with similar modality.
Broad incumbents
- ImmunityBio: Larger oncology-focused biotech with an approved NK cell therapy (Anktiva) and a broader portfolio of NK, T-cell, and antibody-based immunotherapies. Comparable as an established NK cell therapy competitor with regulatory and commercial experience.
- Bristol-Myers Squibb: Global pharmaceutical leader with multiple approved CAR-T therapies (Breyanzi, Abecma) and significant investment in NK and next-generation cell therapy platforms. Sets the strategic benchmark and partnership/acquisition universe for clinical-stage cell therapy companies like Cartherics.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Cartherics Pty Ltd social profiles
Digital presenceCartherics Pty Ltd compliance and trust
Trust signalCompliance1 record
Cartherics Pty Ltd financial estimates
Financial estimateRevenue estimate
Valuation estimate
Cartherics Pty Ltd leadership team
Management profileNumber of profiles
Profiles6 records
Cartherics Pty Ltd funding detail
Funding detailFunding overview
Funding rounds2 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Cartherics Pty Ltd M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Cartherics Pty Ltd
What does Cartherics Pty Ltd do?
Cartherics develops off-the-shelf allogeneic CAR-NK (Chimeric Antigen Receptor Natural Killer) cell therapies derived from induced pluripotent stem cells (iPSCs). Its lead candidate, CTH-401, targets the TAG-72 tumor antigen for the treatment of ovarian cancer, with the broader pipeline aimed at solid tumors and endometriosis. Manufacturing leverages a cGMP-compliant iPSC line licensed from Catalent.
Is Cartherics Pty Ltd a public or private company?
Cartherics Pty Ltd is a private company. It is classified as venture growth investor backed and is currently operating.
When was Cartherics Pty Ltd founded?
Cartherics Pty Ltd was founded in 2014. It employs 11 to 50 people.
Where is Cartherics Pty Ltd based?
Cartherics Pty Ltd is headquartered in Melbourne, Australia, in the Oceania region.
How does Cartherics Pty Ltd make money?
Two revenue lines are on record. Cell Therapy Commercialization is the primary driver. The others are licensing and Manufacturing Partnerships.
Who are Cartherics Pty Ltd's main competitors?
Emerging players on record are Gamida Cell and Caribou Biosciences. Direct peers are Century Therapeutics, Fate Therapeutics, MiNK Therapeutics, Nkarta Therapeutics, Allogene Therapeutics and Shoreline Biosciences. Broad incumbents are ImmunityBio and Bristol-Myers Squibb.
Does Cartherics Pty Ltd have an API?
No public API is recorded for Cartherics Pty Ltd.
What industry is Cartherics Pty Ltd in?
Cartherics Pty Ltd's product category is Cancer Immunotherapy / Cell Therapy. Its primary akta.pro industry code is HLAAABAD, NK Cell Therapies, with a secondary code of HLAAABAB, Cell Therapy Developers (Allogeneic/Off-the-shelf). Its NAICS code is 541714 and its SIC code is 2836.